Pub Date : 2018-01-01DOI: 10.17925/usor.2018.11.1.56
Mohammad M. Shehadeh, M. Akkawi, Ammar A. Aghbar
Purpose: To present the diagnosis and management of the youngest-described keratoconus patient, despite the absence of any systemic or local risk factors except the presence of a strongly positive family history of keratoconus. Methods: A retrospective case report. Results: A 4-year-old female child with free past medical and ocular histories, and a strongly positive family history of keratoconus, presented with deterioration in her vision in the previous 6 months as observed by the family. Objective/subjective refraction showed high astigmatism. Corneal tomography using the Scheimpflug camera Pentacam® HR confirmed the diagnosis of keratoconus in both eyes. Conventional corneal collagen crosslinking (CXL) procedure was performed shortly with a stabilization effect observed over a 1-year follow up period. Conclusion: Keratoconus onset may occur in early childhood, especially in patients with strong family history of the disease even in the absence of systemic or ocular risk factors. So, early screening before the age of 4 years should be done for all children of a family history of keratoconus. Crosslinking may be an effective and safe procedure for very young patients diagnosed with keratoconus.
{"title":"Keratoconus in a 4-year-old Girl with a Strong Family History of Keratoconus","authors":"Mohammad M. Shehadeh, M. Akkawi, Ammar A. Aghbar","doi":"10.17925/usor.2018.11.1.56","DOIUrl":"https://doi.org/10.17925/usor.2018.11.1.56","url":null,"abstract":"Purpose: To present the diagnosis and management of the youngest-described keratoconus patient, despite the absence of any systemic or local risk factors except the presence of a strongly positive family history of keratoconus. Methods: A retrospective case report. Results: A 4-year-old female child with free past medical and ocular histories, and a strongly positive family history of keratoconus, presented with deterioration in her vision in the previous 6 months as observed by the family. Objective/subjective refraction showed high astigmatism. Corneal tomography using the Scheimpflug camera Pentacam® HR confirmed the diagnosis of keratoconus in both eyes. Conventional corneal collagen crosslinking (CXL) procedure was performed shortly with a stabilization effect observed over a 1-year follow up period. Conclusion: Keratoconus onset may occur in early childhood, especially in patients with strong family history of the disease even in the absence of systemic or ocular risk factors. So, early screening before the age of 4 years should be done for all children of a family history of keratoconus. Crosslinking may be an effective and safe procedure for very young patients diagnosed with keratoconus.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67621904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/usor.2018.11.1.38
Vanessa Vera, I. Ahmed, I. Stalmans, H. Reitsamer
T he surgical management of glaucoma offers the potential to lower intraocular pressure (IOP) independent of patients’ compliance with their medication regimen. Procedures such as trabeculectomy and tube shunt placement often yield large magnitudes of IOP reduction, but may be associated with shortand long-term complications. Microinvasive glaucoma surgery (MIGS) offers an alternative surgical approach that is inherently less invasive; however, most devices that fit in this category are associated with a lesser degree of IOP-lowering efficacy compared with traditional glaucoma surgeries. A newer MIGS device, a gel stent that facilitates drainage to the subconjunctival space, appears to offer similar IOP reduction to trabeculectomy, but with much less tissue manipulation; better predictability; and less sight-threatening complications, thus making it a potentially safer and more predictable surgical option in appropriate patients. The following proposed protocol, based on evidence-based practices and augmented where necessary by the opinions of experienced surgeons, provides guidance for the pre-, intra-, and postoperative management of patients receiving a gel stent implant. The goal of this protocol is to provide a framework for better patient selection and preparation, surgical pearls, and how best to assess and manage patients in the postoperative period.
{"title":"Gel Stent Implantation—Recommendations for Preoperative Assessment, Surgical Technique, and Postoperative Management","authors":"Vanessa Vera, I. Ahmed, I. Stalmans, H. Reitsamer","doi":"10.17925/usor.2018.11.1.38","DOIUrl":"https://doi.org/10.17925/usor.2018.11.1.38","url":null,"abstract":"T he surgical management of glaucoma offers the potential to lower intraocular pressure (IOP) independent of patients’ compliance with their medication regimen. Procedures such as trabeculectomy and tube shunt placement often yield large magnitudes of IOP reduction, but may be associated with shortand long-term complications. Microinvasive glaucoma surgery (MIGS) offers an alternative surgical approach that is inherently less invasive; however, most devices that fit in this category are associated with a lesser degree of IOP-lowering efficacy compared with traditional glaucoma surgeries. A newer MIGS device, a gel stent that facilitates drainage to the subconjunctival space, appears to offer similar IOP reduction to trabeculectomy, but with much less tissue manipulation; better predictability; and less sight-threatening complications, thus making it a potentially safer and more predictable surgical option in appropriate patients. The following proposed protocol, based on evidence-based practices and augmented where necessary by the opinions of experienced surgeons, provides guidance for the pre-, intra-, and postoperative management of patients receiving a gel stent implant. The goal of this protocol is to provide a framework for better patient selection and preparation, surgical pearls, and how best to assess and manage patients in the postoperative period.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/USOR.2018.11.2.91
M. Nagpal, Gujarat India
Optical coherence tomography angiography (OCTA) is a new revolutionary non-invasive imaging modality, built on the platform of optical coherence tomography (OCT). This technique works on the principle of ‘decorrelation’ and is still a nascent technology in its infancy with tremendous potential applicability for diagnosing retinal and choroidal vascular diseases. Its non-invasive nature, and the ability to generate images of retinal and choroidal vasculature, allows it to replace and/or supplement the current angiographic gold standards, fluorescein angiography (FA) and indocyanine green angiography (ICGA), if not in all but certainly in most retinal and choroidal pathologies. Still, there exists a major challenge in terms of its wide-scale availability, equipment and processing techniques, presence of artifacts, limitations of imaging capability, and lack of common vocabulary among retinal specialists for interpretation. In this review we intend to describe this novel technique by highlighting its key features, and comparing it with FA and ICGA. We will also discuss its applicability in various clinical scenarios such as diabetic retinopathy, age-related macular degeneration, retinal venous occlusion, choroiditis, and in routine practice. Further studies are needed to more definitively determine OCTA’s utility in the clinical setting and to establish if this technology may offer a non-invasive option of visualizing the retinal vasculature in detail.
{"title":"Optical Coherence Tomography Angiography","authors":"M. Nagpal, Gujarat India","doi":"10.17925/USOR.2018.11.2.91","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.2.91","url":null,"abstract":"Optical coherence tomography angiography (OCTA) is a new revolutionary non-invasive imaging modality, built on the platform of optical coherence tomography (OCT). This technique works on the principle of ‘decorrelation’ and is still a nascent technology in its infancy with tremendous potential applicability for diagnosing retinal and choroidal vascular diseases. Its non-invasive nature, and the ability to generate images of retinal and choroidal vasculature, allows it to replace and/or supplement the current angiographic gold standards, fluorescein angiography (FA) and indocyanine green angiography (ICGA), if not in all but certainly in most retinal and choroidal pathologies. Still, there exists a major challenge in terms of its wide-scale availability, equipment and processing techniques, presence of artifacts, limitations of imaging capability, and lack of common vocabulary among retinal specialists for interpretation. In this review we intend to describe this novel technique by highlighting its key features, and comparing it with FA and ICGA. We will also discuss its applicability in various clinical scenarios such as diabetic retinopathy, age-related macular degeneration, retinal venous occlusion, choroiditis, and in routine practice. Further studies are needed to more definitively determine OCTA’s utility in the clinical setting and to establish if this technology may offer a non-invasive option of visualizing the retinal vasculature in detail.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"91"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/USOR.2018.11.2.79
Sona N Shah, J. Berry
Retinoblastoma is a primary intraocular cancer that develops in the eyes of children. The vast majority of retinoblastoma tumorigenesis is initiated by a mutation in the RB1 gene on chromosome 13q. This practice pearl will discuss the current treatment modalities for this pediatric tumor, with the primary goal of saving the child's life. With recent treatment advances, more emphasis has been placed on successfully saving the eye, often with useful vision.
{"title":"Pearls for Treating Retinoblastoma","authors":"Sona N Shah, J. Berry","doi":"10.17925/USOR.2018.11.2.79","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.2.79","url":null,"abstract":"Retinoblastoma is a primary intraocular cancer that develops in the eyes of children. The vast majority of retinoblastoma tumorigenesis is initiated by a mutation in the RB1 gene on chromosome 13q. This practice pearl will discuss the current treatment modalities for this pediatric tumor, with the primary goal of saving the child's life. With recent treatment advances, more emphasis has been placed on successfully saving the eye, often with useful vision.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"79"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/USOR.2018.11.1.17
D. Dhaliwal
Support: No external funding was received in the publication of this article. Refractive lens exchange (RLE) is frequently used as a refractive surgical procedure for the correction of high presbyopia and high hyperopia, for which laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) or phakic intraocular lens (IOL) refractive surgery is unsuitable. In an expert interview, Deepinder K Dhaliwal, Professor of Ophthalmology at the University of Pittsburgh School of Medicine, Director of Cornea and Refractive Surgery at the UPMC Eye Center, and Associate Medical Director of the Charles T Campbell Ocular Microbiology Laboratory, discusses the challenges of refractive lens exchange and other aspects of refractive surgery.
支持:本文的出版没有收到外部资助。屈光性晶状体置换术(RLE)经常被用作高度老花眼和高度远视的矫正手术，而激光辅助原位角膜磨除术(LASIK)、光屈光性角膜切除术(PRK)或有晶状体人工晶状体(IOL)的屈光手术不适合这种手术。在一次专家访谈中，匹兹堡大学医学院眼科学教授、UPMC眼科中心角膜和屈光手术主任、Charles T Campbell眼部微生物实验室副医学主任Deepinder K Dhaliwal讨论了屈光晶状体置换和屈光手术其他方面的挑战。
{"title":"Updates and Challenges in Refractive Lens Exchange","authors":"D. Dhaliwal","doi":"10.17925/USOR.2018.11.1.17","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.1.17","url":null,"abstract":"Support: No external funding was received in the publication of this article. Refractive lens exchange (RLE) is frequently used as a refractive surgical procedure for the correction of high presbyopia and high hyperopia, for which laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) or phakic intraocular lens (IOL) refractive surgery is unsuitable. In an expert interview, Deepinder K Dhaliwal, Professor of Ophthalmology at the University of Pittsburgh School of Medicine, Director of Cornea and Refractive Surgery at the UPMC Eye Center, and Associate Medical Director of the Charles T Campbell Ocular Microbiology Laboratory, discusses the challenges of refractive lens exchange and other aspects of refractive surgery.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USOR.2017.10.02.119
Joan W Miller, Saghar Bagheri, Demetrios G Vavvas
While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive to date, with a lack of effective therapies and increasing prevalence of the disease. There is an overwhelming need to improve the classification system of AMD, to increase our understanding of cell death mechanisms involved in both neovascular and non-neovascular AMD, and to develop better biomarkers and clinical endpoints to eventually be able to identify better therapeutic targets-especially early in the disease process. There is no doubt that it is a matter of time before progress will be made and better therapies will be developed for non-neovascular AMD.
{"title":"Advances in Age-related Macular Degeneration Understanding and Therapy.","authors":"Joan W Miller, Saghar Bagheri, Demetrios G Vavvas","doi":"10.17925/USOR.2017.10.02.119","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.02.119","url":null,"abstract":"<p><p>While the development of anti-vascular endothelial growth factor (anti-VEGF) as a therapy for neovascular age-related macular degeneration (AMD) was a great success, the pathologic processes underlying dry AMD that eventually leads to photoreceptor dysfunction, death, and vision loss remain elusive to date, with a lack of effective therapies and increasing prevalence of the disease. There is an overwhelming need to improve the classification system of AMD, to increase our understanding of cell death mechanisms involved in both neovascular and non-neovascular AMD, and to develop better biomarkers and clinical endpoints to eventually be able to identify better therapeutic targets-especially early in the disease process. There is no doubt that it is a matter of time before progress will be made and better therapies will be developed for non-neovascular AMD.</p>","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"10 2","pages":"119-130"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.17925/USOR.2017.10.02.119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35613939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USOR.2017.10.01.39
S. Mosaed
I n the largest randomized clinical trial to date on a minimally invasive glaucoma surgery device, the CyPass ® Micro-Stent was able to lower intraocular pressure (IOP) more than was modern cataract surgery (phacoemulsification and intraocular lens implantation) alone, and should be considered for patients with mild to moderate glaucoma already scheduled to undergo phacoemulsification surgery. The two-year outcomes of the COMPASS study found mean IOP reductions of 7.4 mmHg in the CyPass Micro-Stent group and no vision-threatening adverse events; more than 98% of subjects in the CyPass Micro-Stent group achieved 20/40 or better best-corrected visual acuity.
{"title":"Minimally Invasive Glaucoma Surgery and CyPass® Micro-Stent—A New Era in Glaucoma Surgery","authors":"S. Mosaed","doi":"10.17925/USOR.2017.10.01.39","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.01.39","url":null,"abstract":"I n the largest randomized clinical trial to date on a minimally invasive glaucoma surgery device, the CyPass ® Micro-Stent was able to lower intraocular pressure (IOP) more than was modern cataract surgery (phacoemulsification and intraocular lens implantation) alone, and should be considered for patients with mild to moderate glaucoma already scheduled to undergo phacoemulsification surgery. The two-year outcomes of the COMPASS study found mean IOP reductions of 7.4 mmHg in the CyPass Micro-Stent group and no vision-threatening adverse events; more than 98% of subjects in the CyPass Micro-Stent group achieved 20/40 or better best-corrected visual acuity.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"10 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USOR.2017.10.01.46
Sepehr Bahadorani, M. Singer
T he treatment of diabetic macular edema (DME) has become one of the most challenging management issues faced by ophthalmologists in daily practice. This is partly due to the multifactorial nature of DME, progression of the disease and the clinical capacity needed to administer intravitreal injections. In recent years, the treatment options for DME have expanded to include intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents and steroids, and most recently, the use of intravitreal implants. In determining clinically relevant endpoints for clinical studies of these treatments, it is important to consider the patient’s journey and experience with a treatment over a specific time-period rather than isolated outcomes at a pre-specified time-point. Area under the curve (AUC) is an ideal tool for data analysis particularly when it comes to sustained release therapies such as dexamethasone (Ozurdex®, Allergan Inc., California, US) and intravitreal fluocinolone acetonide implant (0.2μg/day FAc implant; Iluvien®, Alimera Sciences Inc., Georgia, US). Unlike single time-point outcomes, AUC analysis provides the average letters gained per day over the entire treatment period, providing a better measure of long-term effectiveness. A recent analysis using the AUC approach highlights the significant visual acuity benefit resulting from the 0.2μg/day fluocinolone acetonide (FAc) implant during the FAME (Fluocinolone Acetonide for Macular Edema) trials. A step-by-step instruction is included in this article that allows statistical analysis of the AUC data from both functional and anatomical outcomes, using a free software tool to further facilitate the use of this technique for future investigators.
{"title":"The Value of Area Under the Curve Analysis as an Outcome Measure in the Assessment of a Continuous Microdosing Fluocinolone Acetonide Implant (ILUVIEN","authors":"Sepehr Bahadorani, M. Singer","doi":"10.17925/USOR.2017.10.01.46","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.01.46","url":null,"abstract":"T he treatment of diabetic macular edema (DME) has become one of the most challenging management issues faced by ophthalmologists in daily practice. This is partly due to the multifactorial nature of DME, progression of the disease and the clinical capacity needed to administer intravitreal injections. In recent years, the treatment options for DME have expanded to include intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents and steroids, and most recently, the use of intravitreal implants. In determining clinically relevant endpoints for clinical studies of these treatments, it is important to consider the patient’s journey and experience with a treatment over a specific time-period rather than isolated outcomes at a pre-specified time-point. Area under the curve (AUC) is an ideal tool for data analysis particularly when it comes to sustained release therapies such as dexamethasone (Ozurdex®, Allergan Inc., California, US) and intravitreal fluocinolone acetonide implant (0.2μg/day FAc implant; Iluvien®, Alimera Sciences Inc., Georgia, US). Unlike single time-point outcomes, AUC analysis provides the average letters gained per day over the entire treatment period, providing a better measure of long-term effectiveness. A recent analysis using the AUC approach highlights the significant visual acuity benefit resulting from the 0.2μg/day fluocinolone acetonide (FAc) implant during the FAME (Fluocinolone Acetonide for Macular Edema) trials. A step-by-step instruction is included in this article that allows statistical analysis of the AUC data from both functional and anatomical outcomes, using a free software tool to further facilitate the use of this technique for future investigators.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"39 1","pages":"46"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USOR.2017.10.01.57
Christopher D Conrady, M. Hartnett
Acknowledgements: This work was supported in part by an unrestricted grant from Research to Prevent Blindness to the University of Utah’s Department of Ophthalmology and Visual Sciences and National Eye Institute R01 grants EY015130 and EY017011 to MEH. M. Elizabeth Hartnett has received NIH grant support as principal investigator for the following: R01EY015130, R01EY017011, T35EY026511. The authors would also like to thank Lane Bennion for the medical renderings.
致谢:这项工作部分得到了美国犹他大学眼科学与视觉科学系预防失明研究中心和美国国家眼科研究所R01基金EY015130和EY017011对MEH的无限制资助。M. Elizabeth Hartnett已获得NIH拨款支持，担任以下项目的首席研究员:R01EY015130, R01EY017011, T35EY026511。作者还想感谢Lane Bennion提供的医学渲染图。
{"title":"The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity","authors":"Christopher D Conrady, M. Hartnett","doi":"10.17925/USOR.2017.10.01.57","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.01.57","url":null,"abstract":"Acknowledgements: This work was supported in part by an unrestricted grant from Research to Prevent Blindness to the University of Utah’s Department of Ophthalmology and Visual Sciences and National Eye Institute R01 grants EY015130 and EY017011 to MEH. M. Elizabeth Hartnett has received NIH grant support as principal investigator for the following: R01EY015130, R01EY017011, T35EY026511. The authors would also like to thank Lane Bennion for the medical renderings.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"10 1","pages":"57"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.17925/USOR.2017.10.02.89
Brandon J. Baartman, John P Berdahl
{"title":"Recent Advances in the Understanding and Treatment of Glaucoma","authors":"Brandon J. Baartman, John P Berdahl","doi":"10.17925/USOR.2017.10.02.89","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.02.89","url":null,"abstract":"","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"10 1","pages":"89"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：